ITP Education Kit
Learn more about ITP and WinRho® when you order the ITP Educational Resource Kit
ITP Juego Educativo
Aprenda más acercade ITPy WinRho® cuando usted ordena el ITP Juego Educativo de Recurso
Efficacy *
WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] is effective in increasing platelet levels in Rh-positive patients. 1,2
* Study was performed using WinRho®/WinRho® SD
† Dose = 20-75 µg/kg (100-375 IU/kg); Response - Platelet increase to ≥ 20,000/mm3
‡ Dose = 25-55 µg/kg (125-275 IU/kg); Response = platelet increase to ≥ 50,000/mm3 and doubling of baseline platelet count
WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized1
In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similar elimination half-lives. WinRho® SDF must be administered via the intravenous route for the treatment of ITP.
*Study was performed using WinRho®/WinRho® SD
† 25µg/kg (125 IU/kg) for 2 days
Please see the Important Risk Information for WinRho® SDF for more detailed risk information and the Prescribing Information for full prescribing details.
- WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation,WestlakeVillage, CA, USA, April 2006.
- Data on file, Cangene Corporation, Baxter Healthcare Corporation.
